ArticleBritish journal of cancer2014

HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.

Y J Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.